Hyperhomocysteinemia – is it still the only interesting but diagnostically unsignificant finding?
Authors:
J. Hyánek 1; J. Matoušková 2; P. Kmoníček 2; P. Formánek 2; V. Kožich 5; J. Zeman 6; M. Orendáč 5; M. Janošík 6; P. Lepší 2; K. Kopřiva 2; L. Dubská 1; J. Dvořáková 1; H. Veselá 1; K. Kupka 4; B. Malec 4; H. Pejznochová 1; R. Hoffmann 1; J. Balasz 1; V. Martiníková 1; M. Vodičková 1; J. Pola 3; V. Maťoška 1; K. Koubek 2
Authors‘ workplace:
oddělení klinické biochemie, metabolická a hematologická ambulance Nemocnice Na Homolce, Praha, přednosta prof. MUDr. J. Hyánek, DrSc.
1; koronární jednotka intenzivní péče kardiologického oddělení Nemocnice Na Homolce, Praha, přednosta prof. MUDr. P. Niederle, DrSc.
2; interní oddělení Nemocnice, Tanvald, přednosta prim. MUDr. J. Pola
3; Ústav nukleární medicíny 1. lékařské fakulty UK a VFN, Praha, přednosta prof. MUDr. T. Šámal, DrSc.
4; Ústav dědičných metabolických poruch 1. lékařské fakulty UK, Praha, přednosta prof. MUDr. M. Elleder, DrSc.
5; Klinika dětí a dorostu 1. lékařské fakulty UK a VFN, Praha, přednosta doc. MUDr. J. Hoza, CSc.
6
Published in:
Vnitř Lék 2005; 51(4): 462-470
Category:
Case Reports
Overview
After „metabolic prologue“ the authors describe 4 cases of the patients at whom the high level of homocystein in serum was detected within hospitalisation at intensive care unit of Hospital Na Homolce. There are the cases of typical homocysteinurie with hereditary deficit of cystathionin-beta-synthase enzyme recognized only after a passed myocardial infarct. The next there were a myocardial infarct within suspect pernicious anaemia, an acute pulmonary embolism with till the time not diagnosed pernicious anaemia and finally a deep flebothrombosis with diagnosed pernicious anaemia but insufficiently treating for allergic reaction. The important homocysteinemie, which is occurred at all these patients, was as a result of an important deficit of cobalamin in remethyl reaction removing homocystein from plasma. The inclusion of homocystein examination into the routine diagnostic process could be fecund first of all in the patients with cardiovascular handicap; without changes of lipid spectrum and risk factors.
Key words:
homocysteine – hyperhomocysteinemia – homocystinuria – vitamin B12 deficiency – folate deficiency – risk factors – atherosclerosis
Sources
1. Chambers J. Homocysteine and vascular disease. Euromedlab Barcelona 2003, 50.
2. Chapman MJ, Huby T, Nigon J. Lipoprotein( a) implication in atherogenesis. Atherosclerosis 1994; 110: 69–72.
3. Clarke R, Lewington S. Homocysteine and prediction of coronary heart disease and stroke. Klin Biochem Metab 2003; 11(32): 132–135.
4. Constans J, Blonn DA, Resplandy F et al. Three months supplementation of hyperhomocysteinemic patients with folic acid and vitamin B6 improves biological markers of endothelial dysfunction. Brit J Haematol 1999; 107: 776–778.
5. Dong C, Yoon W, Goldschmidt-Clermont PJ. DNA Methylation and Atheroslerosis. J Nutr 2002; 132: 2406S– 2409S.
6. Dubská L, Hyánek J, Pejznochová H et al. Stanovení celkového homocysteinu homogenní enzymatickou metodou na analyzátoru Synchron LX20, Beckman Coulter. Klin Biochem Metab 2003; 11(32): 231–234.
7. Friso S, Choi SW, Girelli D et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 2002; 99: 5606–5611.
8. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular diseases: a common mutation in methylentetrahydrofolate reductase. Nature Genet 1995; 10: 111–113.
9. Green R, Miller JW. Folate deficiency beyond megaloblastic anemia: hyperhomocysteinemia and other manifestations of dysfunctional folate status. Semin Hematology 1999; 36: 47–64.
10. Harpel PC, Chang VT, Boirth W et al. Homocysteine and other sulfhydryl compounds enhance the binding of Lp(a) to fibrin: a potential biochemicallink between thrombosis, atherogenesis and sulfhydryl compound metabolism. Proc Nat Acad Sci USA 1992; 89.
10193–10197.
11. Hyánek J, Kavka J, Seemanová E. Homocystinurie. Čs Pediat 1972; 27: 394–398.
12. Hyánek J, Matoušková J, Kmoníček P. Selektivním screeningem detekovaná homocystinurie až po Q–infarkt myokardu na koronární jednotce. Cor et Vasa 2003; 45(9): 459–462.
13. Hyánek J. Hyperhomocysteinemie a její diagnostický význam u pacientů na jednotkách intenzivní péče. Grant č. NA 6497–3, IGA MZČR, 2003.
14. James SJ, Melnyk S, Pogribna M et al. Evaluation in S-Adenosylhomocysteine and DNA Hypomethylation: Potential Epigenetic Mechanism for Homocysteine-related Pathology. J Nutr 2002; 132(Suppl): 2361S–2366S.
15. Joosten E, v. den Berg A, Riezler R et al. Metabolic evidence thet deficiencies of vitamin B-12 (cobalamin), folate, and vitamin B-6 occur commonly in elderly people. Am J Clin Nutr 1993; 58: 468–476.
16. Kang SS,Wong PW, Bock HG et al. Intermediate hyperhomocysteinemia resulting from compound heterozygozity of methyltetrahdyrofolate reductase mutations. Am J Hum Genet 1991; 48: 546–551.
17. Kožich V, Kraus J, Hyánek J. Homocystein, geny a vitaminy: souvislost s kardiovaskulárním onemocněním a komplikacemi v těhotenství. DMEV 1999; 3: 113–120.
18. Lindebaum J, Rosenberg IH, Wilson P et al. Prevalence of cobalamin deficiency in the Framingham elderly. J Clin Nutr 1994; 60: 2–11.
19. Lucoc M. Is folic acid the ultimate functional food component for disease prevention? BMJ 2004; 328: 211–214.
20. Lucoc M. Folic acid: nutritional biochemistry, molecular biology and role in disease processes. Mol Genet Metab 2000; 71: 121–128.
21. Malinow MR, Bostom AG, Krauss RG. Homocyst(e)ine, diet and cardiovascular diseases: a statement for health care professionals from Nutrition Comittee American Heart Association. Circulation 1999; 99: 178–182.
22. Matalon R, Rady S, Szucs K et al. Polymorphismus MTHFR and MTRR in Czech Patients with Cardiovascular Diseases and Stroke. Čes Slov Pediatrie 2003, 58: 403–404.
23. McCulley KS, Radsgale BD. Production of atherosclerosis by homocysteinemia. Am J Pathol 1970; 61: 1–8.
24. Nygaard O, Vollset SE, Refsum H. Total plasma homocysteine and cardiovasular risk profile. J Amer Med Ass 1995; 274: 1526–1533.
25. Orendáč M, Kožich V, Zeman J et al. Klinický obraz homocystinurie z deficitu cystathionin-beta-syntházy u devatenácti českých a slovenských pacientů. Čas Lék Čes 2000; 139: 500–507.
26. Ravnskov U, Pollmeer U. Mythhos Cholesterin: die Zehn Grösten Irtümer. Stuttgart: S Hirzel Verlag 2002.
27. Scriver CR, Beaudet AL, Sly WS et al. The metabolic and genetic bases of inherited disease. New York: McGraw Hill 1995.
28. Selhub J. Homocysteine metabolism. Ann Rev Nutr 1999; 19: 217–246.
29. Stanger O, Herrmann W, Pietrzik K et al. Koncensus der D.A.CH. – Liga Homocystein über der rationallen kardiovaskularen und trombotischen Erkrankungen-Richtlinien und Empfehlungen. J Kardiol 2003; 10(5): 190–199.
30. Škodová Z, Píša Z, Poledne R et al. Je nedávný pokles cholesterolemie v ČR průkazný? Čas Lék Čes 1996; 135: 589–593.
31. Švehlová M, Štěpánková L, Kaupcová P et al. Trombóza portální žíly u pacienta s hyperhomocysteinemií. Vnitř Lék 2002; 48(7): 671–674.
32. Ueland J et al. The Hordaland Homocysteine Studies. Lipids 2001; 36: S33–S39.
33. Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease: possible role of methionine metabolism. J Clin Invest 1976; 57: 1079–1082.
34. Worthley SG et al. Coronary artery disease: pathogenesis and acute coronary syndrome. Mt Sinai J Med 2001; 68: 167–181.
35. Familial Hypercholesterolemia. Report of WHO Consultations. WHO Press, 1998.
36. Harmonized Clinical Guidelines on Prevention of Atherosclerotic Vascular Disease. Executive Summary IAS 2003.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2005 Issue 4
Most read in this issue
- The pleural effusion in general internal practice
- Klinický význam mírně zvýšených hodnot α−fetoproteinu v séru u pacientů s chronickou hepatitidou C a B
- Aortic stenosis, sclerosis, and atherosclerosis
- Hyperhomocysteinemia – is it still the only interesting but diagnostically unsignificant finding?